New breast cancer cocktail aims to ditch chemo before surgery

NCT ID NCT07290166

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how many achieve a complete response in the breast tissue. If it works, this approach could spare patients from chemo side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab, pertuzumab, pyrotinib, CDK4/6 inhibitor, and endocrine therapy
What this could lead to: If successful, this could offer a chemotherapy-free option for certain breast cancer patients, potentially reducing side effects while still shrinking tumors before surgery.
What could go wrong: This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The combination also carries risks like heart problems, diarrhea, and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.